• Latest Posts

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

How is Actelion Spin-Off Idorsia Doing One Year Later?

Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates

New Antiviral for RSV Lung Infections Shows Promise in Phase IIa

Could this British Biotech’s Drug Help to Bring Down COPD Hospitalizations?

Dutch RNA Firm Announces a Public Offering when its Stock is at an All-Time Low


No More Seasonal Flu Shots: British Biotech’s Universal Antiviral Raises £13M

More News! 12 Sep 2017

Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA

Verona Achieves Successful Results for Phase IIa Trial of Deadly Lung Disease Drug

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

French Biotech Lures Big Pharma with Fibrosis Treatments

AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy